PARP1 and cancer: This approach relies on the idea of synthetic lethality, where the inhibition of PARP1 in cancer cells with defective DNA repair mechanisms (such as BRCA1/2 mutations) leads to cell death, while normal ones with intact DNA repair pathways are less affected [9,22].